secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2026-07-30T20:08:07+00:00
Accession:  0001628280-26-051051
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Q2 net loss $15.2M; cash $236.6M; workforce reduction includes CSO departure
--------------------------------------------------------------------------------

- Net loss of $15.2M vs $16.0M in Q2 2025; R&D expense $12.7M (-10% YoY); G&A $4.7M (+23% YoY).
- Cash, equivalents and marketable securities $236.6M; runway projected through mid-2029.
- Workforce reduction in research team; CSO Daniel Lorrain, Ph.D. departing.
- PROPEL-IPF Phase 2 trial of PIPE-791 ongoing with >55 sites in 8 countries; J&J completed enrollment in Phase 2 MDD trial of JNJ-5120/PIPE-307.
- Positive Phase 1b topline data for PIPE-791 in chronic pain; safety consistent with prior trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/0001628280-26-051051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/ctnm-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-051051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer